Physician profile
Brian Ray Harrow
NPI 1023404118
$2,869.29
in general payments reported to CMS, 2019-2025
24 companies · $742 in 2025
The $742 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $136 · 2021: $220 · 2022: $126 · 2023: $574 · 2024: $961 · 2025: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,276.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $586.44 | 2023-2025 | Envista Mx60 Iol, Miebo, Envista Envy Iol |
| Abbvie INC. | $474.66 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $262.37 | 2019-2023 | |
| Astellas Pharma US INC | $224.72 | 2024 | Izervay |
| Tarsus Pharmaceuticals, INC. | $209.83 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $171.05 | 2019-2025 | Clareon, Rocklatan, Lensx |
| Biotissue Holdings INC. | $140.07 | 2025 | |
| Apellis Pharmaceuticals, INC. | $108.80 | 2024 | Syfovre |
| Mallinckrodt Hospital Products INC. | $98.21 | 2021-2023 | Acthar |
| Ocular Therapeutix, INC. | $78.55 | 2023-2025 | Dextenza |
| Amgen INC. | $71.70 | 2024-2025 | Tepezza |
| Allergan, INC. | $65.11 | 2019-2021 | |
| Oyster Point Pharma, INC. | $56.13 | 2023-2024 | Tyrvaya, Ryzumvi |
| Rayner Intraocular Lenses Limited | $46.24 | 2023-2025 | Omidria, Rayone Spheric, Rayone Aspheric |
| Genentech USA, INC. | $44.52 | 2023-2024 | Vabysmo |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $43.96 | 2024 | Iyuzeh |
| Alimera Sciences, INC. | $39.56 | 2023-2024 | Iluvien, Yutiq |
| Glaukos Corporation | $31.11 | 2021 | |
| Kala Pharmaceuticals, INC. | $24.92 | 2021 | |
| New World Medical,INC. | $22.19 | 2021 | |
| Dompe US, INC. | $20.73 | 2021 | |
| Lensar, INC. | $19.12 | 2024 | Lensar Laser System |
| Sight Sciences, INC. | $16.08 | 2019 | |
| Aerie Pharmaceuticals, INC. | $13.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Harrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.